Zacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a sell rating to a hold rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company’s pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson’s disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. “

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright set a $25.00 price target on shares of Epizyme and gave the company a buy rating in a research note on Friday, May 31st. BidaskClub upgraded shares of Acceleron Pharma from a strong sell rating to a sell rating in a research report on Friday, May 10th. Finally, ValuEngine upgraded shares of ZIX from a buy rating to a strong-buy rating in a research report on Saturday, May 4th.

NERV opened at $6.65 on Tuesday. The firm has a 50 day moving average of $5.35. Minerva Neurosciences has a 1-year low of $4.07 and a 1-year high of $12.95. The firm has a market cap of $260.30 million, a P/E ratio of -5.16 and a beta of 1.59.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). Analysts expect that Minerva Neurosciences will post -1.71 EPS for the current year.

In other news, major shareholder Venture Associates L. Index III sold 60,051 shares of Minerva Neurosciences stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $4.69, for a total value of $281,639.19. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Venture Associates L. Index III sold 36,574 shares of Minerva Neurosciences stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $7.05, for a total transaction of $257,846.70. The disclosure for this sale can be found here. Insiders sold a total of 670,558 shares of company stock worth $3,694,870 in the last 90 days. Corporate insiders own 12.00% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. increased its stake in shares of Minerva Neurosciences by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 93,888 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 4,064 shares in the last quarter. GSA Capital Partners LLP increased its stake in shares of Minerva Neurosciences by 16.9% in the 4th quarter. GSA Capital Partners LLP now owns 77,400 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 11,200 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of Minerva Neurosciences by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 11,515 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 8,993 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of Minerva Neurosciences in the 4th quarter valued at $77,000. Finally, Handelsbanken Fonder AB increased its stake in shares of Minerva Neurosciences by 24.4% in the 1st quarter. Handelsbanken Fonder AB now owns 255,000 shares of the biopharmaceutical company’s stock valued at $2,004,000 after acquiring an additional 50,000 shares in the last quarter. Institutional investors own 77.00% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.